GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
BA2810 1A-116Summary: 1A-116 is an inhibitor specific for the W56 residue that effectively prevents the induced activation and blocks the interaction of the -
BA2823 SincalideSummary: Sincalide (Cholecystokininoctapeptide, CCK-8) is a fast-acting cholecystokinin (CCK)'s that is used intravenously during cholecystography. -
BA2827 YUM70Summary: YUM70 is a potent and selective inhibitor of glucose-regulated protein 78. -
BA2884 TegaserodSummary: Tegaserod is an orally effective 5-hydroxytryptamine receptor 4(;) agonist and receptor antagonist. -
BA2894 ARS-853Summary: ARS-853 is a selective, covalent inhibitor. -
BA3557 γ-GlutamylvalineSummary: Gamma-Glutamylvaline is an activator with anti-inflammatory activity. -
A1748 Ramelteon1 CitationTarget: Melatonin ReceptorsSummary: Agonist of melatonin receptor(M1-M2),highly selective -
A1987 Ki164256 CitationTarget: LPA ReceptorsSummary: LPA receptor antagonist -
A5318 Prazosin HClSummary: α1 and α2B-adrenoceptor antagonist -
A5375 TranilastSummary: Angiogenesis inhibitor

